ADMS - Adamas gains 12% on settlement of patent litigation with Zydus

Adamas Pharmaceuticals (ADMS) inks settlement agreement with Zydus Pharmaceuticals resolving its ongoing litigation concerning Zydus’s Abbreviated New Drug Application ((ANDA)) seeking FDA approval to market a generic version of Gocovri (amantadine) extended-release capsules. Under the settlement agreement, Adamas grants Zydus a non-exclusive license to make, use, sell, offer to sell and import generic versions of Gocovri as of March 4, 2030, or earlier, including a potential for an accelerated license date. The parties will submit a joint stipulation and order to the U.S. District Court of New Jersey, and the settlement agreement to U.S. Federal Trade Commission and Department of Justice. Gocovri (amantadine) extended-release capsules is the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson’s disease.Shares up 12% premarket.

For further details see:

Adamas gains 12% on settlement of patent litigation with Zydus